Pay in 4 interest-free payments of $6.40 Learn more
Ships within 48 hours · Estimated delivery Oct 27 - Nov 1
2022 July;208(1):34-42.Full text Engeler D, Baranowski AP, Berghmans B, et al
To Join The Fun Min
As of 2026, published human RCTs specifically on TB-500 (the synthetic fragment) are not available
BPC-157 remains investigational with limited human clinical data
Key Takeaways AOD 9604 produces 2-3 times greater fat loss than placebo in clinical trials with women Standard dosing ranges from 0.5mg to 1mg daily via subcutaneous injection Side effects occur in fewer than 5% of women, primarily mild injection site reactions Results typically become visible after 4-6 weeks of consistent daily administration The peptide preserves lean muscle mass while specifically targeting fat tissue How AOD 9604 Works for Female Fat Loss AOD 9604 functions by activating beta-3 adrenergic receptors in adipose tissue, specifically triggering lipolysis without the growth-promoting effects of full-length growth hormone
